As per reports, IBM (IBM) announced the acquisition of U.S based Octo, an IT modernization and digital transformation services provider serving the U.S. federal government, including health, defense, and civilian agencies. The technology giant’s acquisition of Octo is one of the major digital transformation partnerships with the federal government.
Upon the close of the purchase, Octo’s approximately 1,500 employees will join IBM Consulting’s U.S. public and federal market organization. The acquisition of Octo will enhance IBM’s existing strengths in IT modernization and will enhance its ability to support federal agencies with a flexible and modern approach to digital transformation.
“Governments require agility and resiliency to meet the evolving needs of citizens directly and in real time. The combination of Octo’s highly qualified and respected team with IBM’s consulting expertise, technical capabilities and strategic partner ecosystem will enable federal clients to transform faster and better serve citizens,” stated John Granger, Senior Vice President of IBM Consulting.
The deal is subject to customary closing conditions and regulatory clearances and is expected to close in the fourth quarter of this year.
Dow 30 component International Business Machines Corporation (IBM) provides information technology (IT) products and services worldwide. Please visit the Vista Partners IBM Coverage Page to learn more about International Business Machines Corp (IBM) and track its ongoing progress.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
DID YOU KNOW?
If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently.
